Eli Lilly's $3.8bn psychedelics bet is built on British science

Eli Lilly's first venture into psychedelic medicine, a takeover of AtaiBeckley worth up to $3.8 billion, is above all a vindication of two decades of British research once dismissed as fringe science.

The prize at the centre of the deal is BPL-003, a nasal spray formulation of the psychedelic compound 5-MeO-DMT developed by Beckley Psytech, the Oxford company founded by Amanda Feilding and her son Cosmo Feilding Mellen.

Feilding, who died in May 2025 and was often called the "Queen of Psychedelics", spent decades dragging the field towards scientific respectability through her Beckley Foundation, collaborating with Imperial College London and playing a pivotal role in the world's first LSD brain imaging study.

Her son's company took that work commercial, and its lead compound entered phase III trials for treatment-resistant depression this year, following phase IIb data showing statistically significant improvements in patients from day two, maintained through day 57.

Beckley Psytech merged with Germany's atai Life Sciences last November in a $390 million all-share deal, and barely eight months later the combined company has been swallowed by one of the world's largest drugmakers at almost ten times that valuation.

Lilly will pay $6.75 per share in cash, an upfront equity value of around $2.8 billion and a 26% premium to Wednesday's close, with up to a further $1 billion tied to development and regulatory milestones.

Shares in Nasdaq-listed AtaiBeckley jumped more than 30% on the news.

For Lilly, the company that transformed depression treatment with Prozac, the deal is a bet that the next revolution in psychiatry will work very differently.

Where conventional antidepressants slowly alter brain chemistry, psychedelics are thought to rapidly promote the growth of new neural connections, addressing the lack of brain plasticity seen in patients who do not respond to standard treatments.

Lilly's chief scientific officer, Daniel Skovronsky, said the science of how such drugs bind to brain receptors and trigger neurons to become more plastic is now well understood, even if the field still debates whether the hallucinogenic experience is essential to the effect.

The commercial logic is equally clear.

Jefferies analyst Andrew Tsai estimates BPL-003 could generate sales of $1 billion to $2 billion if late-stage trials succeed, while RBC Capital Markets reckons the psychedelics industry could reach $12 billion in revenue by 2034, rivalling the current $8 billion market for branded antidepressants.

Johnson & Johnson (NYSE:JNJ) has already proved the model, with its ketamine-derived nasal spray Spravato generating $468 million in first-quarter sales, and AbbVie bought Gilgamesh Pharmaceuticals' lead psychedelic candidate for up to $1.2 billion last year.

A friendlier regulatory backdrop under the Trump administration, which has prioritised psychedelic-based treatments for depression and post-traumatic stress disorder, has removed another barrier.

Topline phase III data on BPL-003 is not expected until early 2029, so Lilly is paying $2.8 billion upfront for a drug that is years from market.

That it is willing to do so says much about how far psychedelics have travelled, and how much of that journey began in Oxford.